D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Exclusion Criteria

• •History of or current relevant CNS pathology (current ≥grade 2 epilepsy, seizure, paresis, aphasia, clinically relevant apoplexia, severe brain injuries, dementia, Parkinson's disease, organic brain syndrome, psychosis).
• •Impaired cardiac function, including any one of the following:
• •* LVEF \<45% as determined by MUGA scan or echocardiogram.
• •* Complete left bundle branch block.
• •* Use of a cardiac pacemaker.
• •* ST depression of \>1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads.
• •* Congenital long QT syndrome.
• •* History of or presence of significant ventricular or atrial arrhythmia.
• •* Clinically significant resting bradycardia (\<50 beats per minute).
• •* QTc \>450 msec on screening ECG (using the QTcF formula).
• •* Right bundle branch block plus left anterior hemiblock, bifascicular block.
• •* Myocardial infarction within 3 months prior to starting Dasatinib.
• •* Angina pectoris.
• •Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
• •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
• •History of or current autoimmune disease.
• •Systemic cancer chemotherapy within 2 weeks prior to study.
• •Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation.
• •Active malignancy other than ALL with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix.
• •Active infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator.
• •Nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception during participation in the study and at least three months thereafter.